---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-25-000008"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:47:41.076687+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q4 revenue $321.8M (+6.8% organic); FY2025 adjusted EPS guidance $3.65-$3.75

## Summary
- Q4 revenue $321.8M (+6.8% organic YoY); GAAP EPS $1.02, adjusted EPS $0.81.
- FY2024 revenue $1.25B (+10.7% organic); GAAP EPS $1.16, adjusted EPS $3.38.
- FY2025 guidance: constant-currency revenue growth 5-6%, adjusted EPS $3.65-$3.75, adjusted FCF $135-155M.
- OSPREY sleep apnea study met primary safety and efficacy endpoints at 6 months; RECOVER depression study publications support VNS Therapy.
- Natalia Kozmina appointed Chief Human Resources Officer in January 2025.

## SEC filing metadata
- accession: 0001639691-25-000008
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969125000008/0001639691-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969125000008/livn-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-25-000008
- JSON: https://secwatch.observer/filing/0001639691-25-000008.json
- Plain text: https://secwatch.observer/filing/0001639691-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.